MultiCell Technologies, Inc. (MCET)
U.S. Reporting: SEC Filer
Office: (401) 762-0045 | Email: [email protected] | Web: www.MultiCellTech.com
(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub. For more detailed, up-to-date information on MultiCell Technologies, please go the company website.)
MultiCell inks R&D agreement with Oxis Biotech
MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS)
to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment
of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.
MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.
Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.
Xenogenics Corporation (“Xenogenics”), a development-stage medical device company, is focused on the design of next-generation bioabsorbable stents for interventional cardiology
and peripheral vascular applications. Xenogenics is a majority owned subsidiary of MultiCell Technologies, Inc. (OTCBB: MCET).
Xenogenics' Ideal BioStent™ is a bioabsorbable stent which incorporates Rapamycin providing anti-restenotic therapy similar to today's commonly used drug-eluting metal stents.
Xenogenics' bioabsorbable stent technology allows for the ability to layer different combinations of polymers and drugs, enabling the optimization of the delivery of combination drug therapies to provide
superior clinical results. Xenogenics' Ideal BioStent™ represents a significant advance over currently available stents, including:
* The ability to promote positive vessel remodeling.
* No metal artifact remaining in the patient's body after vessel healing.
* The reduced need for long-term and costly anti-platelet therapy.
MultiCell Technologies, Inc. Corporate Headquarters
MultiCell Technologies, Inc.
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.
Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.
Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.
While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.
The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.